Diakonie-Klinikum Stuttgart Diakonissenkrankenhaus und Paulinenhilfe gGmbH
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
At Diakonie-Klinikum Stuttgart Diakonissenkrankenhaus und Paulinenhilfe gGmbH, clinical research in hematology focuses on blood cancers and related disorders, with studies centered on improving treatment effectiveness and deepening response assessment in multiple myeloma, acute myeloid leukemia, and other lymphoid malignancies.
- Multiple myeloma and newly diagnosed multiple myeloma studies exploring better treatment responses and longer disease control
- Acute myeloid leukemia trials evaluating new treatment strategies for newly diagnosed patients with higher-risk disease
- Acute lymphoblastic leukemia research focused on improving survival and treatment planning in Ph+ ALL
These studies aim to refine how blood cancers are treated, with attention to remission quality, relapse prevention, and more personalized care for patients.
Neoplasms
The site also conducts trials in oncology for aggressive and relapsed cancers, including Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma, with a strong emphasis on testing new combinations and improving outcomes after standard therapy.
- Advanced-stage Hodgkin lymphoma studies comparing approaches that may reduce toxicity while maintaining effectiveness
- Diffuse large B-cell lymphoma research in relapsed or refractory disease, aiming to improve response rates
- Follicular lymphoma and other high-grade lymphoma investigations focused on better disease control
This research supports the development of more effective cancer treatments, especially for patients whose disease is difficult to treat or has returned after earlier therapy.
Translational Treatment Optimization
Several trials at this hospital are designed to compare established therapies with newer options, using measures such as remission depth, minimal residual disease, and survival to guide future care in blood cancers.
- Studies assessing whether newer treatment combinations can improve minimal residual disease negativity in multiple myeloma
- Research comparing treatment approaches that may lower toxicity without reducing effectiveness in lymphoma
- Trials examining whether adding new agents to standard care can improve outcomes in acute leukemia
Overall, the research portfolio reflects a focus on practical advances that could make cancer therapy more precise, more tolerable, and more effective for patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 33 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Universitaet Muenster2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diakonie-Klinikum Stuttgart Diakonissenkrankenhaus und Paulinenhilfe gGmbH
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE-158) | Merck Sharp & Dohme LLC | Phase II | Not Recruiting | Feb 2016 | — |
IMP list
lock Showing 1 of 33 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 3 | Unknown | 2016-07-15 | 2024-04-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.